Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Amortization of Deferred Charges (2016 - 2025)

Historic Amortization of Deferred Charges for Mimedx (MDXG) over the last 14 years, with Q1 2025 value amounting to $135000.0.

  • Mimedx's Amortization of Deferred Charges rose 9565.22% to $135000.0 in Q1 2025 from the same period last year, while for Mar 2025 it was $464000.0, marking a year-over-year increase of 242.83%. This contributed to the annual value of $505000.0 for FY2023, which is 813.7% up from last year.
  • Latest data reveals that Mimedx reported Amortization of Deferred Charges of $135000.0 as of Q1 2025, which was up 9565.22% from $69000.0 recorded in Q1 2024.
  • Mimedx's 5-year Amortization of Deferred Charges high stood at $418000.0 for Q2 2021, and its period low was $69000.0 during Q1 2024.
  • Moreover, its 5-year median value for Amortization of Deferred Charges was $120000.0 (2022), whereas its average is $159357.1.
  • Within the past 5 years, the most significant YoY rise in Mimedx's Amortization of Deferred Charges was 10900.0% (2021), while the steepest drop was 7591.4% (2021).
  • Quarter analysis of 5 years shows Mimedx's Amortization of Deferred Charges stood at $112000.0 in 2021, then rose by 6.25% to $119000.0 in 2022, then rose by 10.92% to $132000.0 in 2023, then tumbled by 47.73% to $69000.0 in 2024, then surged by 95.65% to $135000.0 in 2025.
  • Its Amortization of Deferred Charges was $135000.0 in Q1 2025, compared to $69000.0 in Q1 2024 and $132000.0 in Q4 2023.